Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

We circle back to three small biotech stocks that recently were positively highlighted and moved up on good news. Explore ...

Dr Bianca Ogden and Hashan De Silva share the companies and trials they find interesting in the constantly innovating biotech ...

UBS sold holdings in Concord Biotech, Five Star Business Finance, IIFL Securities, and Marksans Pharma through block deals, ...

Pengana High Conviction Equities Fund portfolio manager James McDonald reckons these three biotechs are primed for growth.

Recursion Pharmaceuticals has an exciting approach to developing therapies. The company recently reported positive phase 2 ...

The end of the trading week likely can't come fast enough for Vanda Pharmaceuticals (NASDAQ: VNDA). The commercial-stage ...

Moderna 's (NASDAQ: MRNA) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...

Sana Biotechnology Inc (SANA) stock saw a modest uptick, ending the day at $4.62 which represents a slight increase of $0.33 or 7.69% from the prior close of $4.29. The stock opened at $4.47 and ...

Beyond MariTide, Amgen has a rich pipeline with more than 30 phase 3 programs. Some are for existing medicines seeking label ...

STAT's podcast The Readout LOUD this week discusses cannabinoid receptor drugs in weight loss, what the Fed's rates cut might ...

Healthcare ETFs hold the potential for higher returns, diversification, and exposure to stably growing companies. Therefore, ...